新一代钠-葡萄糖共转运体-2抑制剂艾托格列净在糖尿病及特殊人群中的治疗价值

Clinical therapeutic value of a new generation of sodium-glucose cotransporter-2 inhibitor ertugliflozin in patients with diabetes and special populations

作为新一代钠-葡萄糖共转运体-2抑制剂,艾托格列净(ertugliflozin, ERT)分子结构更加稳定、半衰期更长、降糖效果显著、耐受性良好且具有独立于降糖作用的心血管保护作用,在国内外均被推荐用作治疗2型糖尿病(T_(2)DM)合并动脉粥样硬化性心血管疾病(ASCVD)的优先选择。此外,ERT对T_(2)DM患者的体重具有确切的控制效果,因此,ERT在T_(2)DM合并肥胖的患者中也具有一定使用价值。但在T_(2)DM合并肾功能不全患者中,ERT的安全性较低,不推荐使用。

As the latest generation of sodium-glucose cotransporter-2 inhibitors(SCLT2i),ertugliflozin(ERT)has stable molecular structure,long half-life,significant hypoglycemic effect and good tolerance.It also has the protective effect of heart independent of its hypoglycemic activity.It is recommended as a priority treatment for the patients with type 2 diabetes mellitus(T_(2)DM)complicated with atherosclerotic cardiovascular disease(ASCVD)in China and abroad.In addition,ERT has a concrete effect on controlling the body weight of T_(2)DM patients,thus also has the value in the treatment of T_(2)DM patients with obesity.However,ERT is not recommended to be used in those T_(2)DM patients with renal insufficiency due to low safety profile.